Literature DB >> 891045

Studies on normal human skeletal muscle in relation to the pathopharmacology of malignant hyperpyrexia.

T E Nelson, M A Denborough.   

Abstract

1. The effects of dantrolene on pharmacologically-induced contractures and potentiated isometric twitches in normal human skeletal muscle have been studied in vitro. 2. Dantrolene sodium, at concentrations of 3 mumol/l or less, attenuates basal twitch, inhibits halothane potentiation of basal twitch and inhibits halothane-potentiated potassium contractures, but has less effect on twitch potentiation by 2 mmol/l caffeine. 3. Caffeine contractures are attenuated by dantrolene concentrations of 12 mumol/l or greater. The effect of dantrolene on caffeine contracture is characterized by decreased contracture tension and by prolonged time to peak contracture. 4. The results indicate that halothane and 2 mmol/l caffeine have agonistic effects on the excitation-contraction (E-C) coupling mechanism, and suggest that they may act at separate E-C coupling sites. The relationships of these findings to the pathopharmacology of malignant hyperpyrexia are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 891045     DOI: 10.1111/j.1440-1681.1977.tb02628.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  8 in total

Review 1.  Etiopathogenetic defect of malignant hyperthermia: hypersensitive calcium-release channel of skeletal muscle sarcoplasmic reticulum.

Authors:  P J O'Brien
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

2.  Masseter contracture and tachycardia causing termination of anesthesia.

Authors:  B W Burger; E Malsch; B W Mayer
Journal:  Anesth Prog       Date:  1984 Nov-Dec

3.  Membrane abnormality in malignant hyperthermia.

Authors:  A Shah; V Sahgal; V Subramani
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 4.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

5.  Malignant hyperthermia: a disease of specific myofiber type?

Authors:  T E Nelson; S S Schochet
Journal:  Can Anaesth Soc J       Date:  1982-03

6.  Porcine malignant hyperthermia--failure of dantrolene dose response to diagnose susceptibility (halothane effect).

Authors:  E H Flewellen; T E Nelson; D E Bee
Journal:  Can Anaesth Soc J       Date:  1980-01

7.  The effect of dantrolene on skeletal-muscle sarcoplasmic-reticulum function in malignant hyperpyrexia in pigs.

Authors:  M D White; J G Collins; M A Denborough
Journal:  Biochem J       Date:  1983-05-15       Impact factor: 3.857

8.  Halothane modulation of skeletal muscle ryanodine receptors: dependence on Ca2+, Mg2+, and ATP.

Authors:  Paula L Diaz-Sylvester; Maura Porta; Julio A Copello
Journal:  Am J Physiol Cell Physiol       Date:  2008-02-27       Impact factor: 4.249

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.